NASDAQ:ACOR Acorda Therapeutics (ACOR) Stock Forecast, Price & News $14.31 -0.93 (-6.10%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$14.27▼$15.0350-Day Range$11.55▼$17.6052-Week Range$5.22▼$24.80Volume6,275 shsAverage Volume24,876 shsMarket Capitalization$17.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Acorda Therapeutics (NASDAQ:ACOR) StockAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Read More ACOR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACOR Stock News HeadlinesSeptember 22, 2023 | americanbankingnews.comAcorda Therapeutics (NASDAQ:ACOR) Share Price Crosses Above 200 Day Moving Average of $13.34September 20, 2023 | msn.comAcorda: PNP, NBI investigating Surigao del Norte ‘cult’ abuse allegationsSeptember 27, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.September 11, 2023 | stocknews.com3 Biotech Stocks to Buy under $20August 28, 2023 | finance.yahoo.comAcorda Therapeutics (ACOR): A Comprehensive Analysis of Its Market ValueAugust 8, 2023 | finance.yahoo.comAcorda Therapeutics Reports Second Quarter 2023 Financial ResultsAugust 2, 2023 | finance.yahoo.comAcorda Therapeutics Announces Launch of New INBRIJA® Campaign: "For The Fighters™"August 1, 2023 | finance.yahoo.comAcorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023September 27, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.July 17, 2023 | finance.yahoo.comAtavistik Bio Appoints Bryan Stuart as Chief Executive OfficerJuly 13, 2023 | stocknews.comTime to Capitalize on These 3 Hot Biotech StocksJune 26, 2023 | finance.yahoo.comAcorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price RequirementJune 26, 2023 | finance.yahoo.comAcorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJune 5, 2023 | finance.yahoo.comLittle Excitement Around Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) RevenuesJune 2, 2023 | finance.yahoo.comAcorda Therapeutics Announces Completion of 1-for-20 Reverse Stock SplitMay 31, 2023 | msn.comAcorda Therapeutics launches 1-for-20 reverse stock splitMay 31, 2023 | finance.yahoo.comAcorda Therapeutics to Conduct 1-for-20 Reverse Stock SplitMay 17, 2023 | insidermonkey.comAcorda Therapeutics, Inc. (NASDAQ:ACOR) Q1 2023 Earnings Call TranscriptMay 12, 2023 | finance.yahoo.comQ1 2023 Acorda Therapeutics Inc Earnings CallMay 12, 2023 | marketwatch.com8-K: Acorda Therapeutics, Inc.May 11, 2023 | msn.comCapricor Therapeutics GAAP EPS of -$0.31 beats by $0.01, revenue of $2.98M beats by $2.48MMay 11, 2023 | msn.comAcorda Therapeutics GAAP EPS of -$0.69 beats by $0.42, revenue of $22.25M misses by $8.76MMay 10, 2023 | msn.comAcorda Therapeutics down 8%, makes $6.2M interest payment in cashMay 10, 2023 | finance.yahoo.comAcorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in CashMay 9, 2023 | thestreet.comAcorda Stock Gaps Up On Today's Open (ACOR)May 8, 2023 | barrons.comAcorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA(R) in ChinaMay 8, 2023 | marketwatch.comAcorda Therapeutics Shares Soar 75% After Signing China Distribution Deal for InbrijaSee More Headlines Receive ACOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACOR Company Calendar Last Earnings8/08/2023Today9/27/2023Next Earnings (Estimated)11/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ACOR CUSIP00484M10 CIK1008848 Webwww.acorda.com Phone(914) 347-4300Fax914-347-4560Employees111Year Founded1995Profitability EPS (Most Recent Fiscal Year)($21.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,920,000.00 Net Margins-17.89% Pretax Margin-18.02% Return on Equity-26.63% Return on Assets-5.47% Debt Debt-to-Equity Ratio2.60 Current Ratio2.14 Quick Ratio1.65 Sales & Book Value Annual Sales$118.57 million Price / Sales0.16 Cash FlowN/A Price / Cash FlowN/A Book Value$77.13 per share Price / Book0.19Miscellaneous Outstanding Shares1,240,000Free Float1,210,000Market Cap$18.51 million OptionableOptionable Beta1.42 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Ron Cohen M.D. (Age 67)Founder, CEO, Pres & Director Comp: $984.15kMr. Michael A. Gesser M.B.A. (Age 60)Chief Financial Officer Comp: $459.15kMr. Kerry M. Clem (Age 53)Chief Commercial Officer Comp: $592.23kMr. Robert Morales (Age 55)Interim Principal Accounting Officer, Principal Financial Officer, VP of Fin. & Controller Ms. Felicia VonellaVP of Investor RelationsMr. Neil S. Belloff Esq. (Age 63)Gen. Counsel & Corp. Sec. Ms. Tierney SaccavinoExec. VP of Corp. CommunicationsMs. Denise J. DucaExec. VP of HRMr. Andrew Mayer J.D.Sr. VPSofia AliSr. VP of Operations & Strategic PlanningMore ExecutivesKey CompetitorsSAB BiotherapeuticsNASDAQ:SABSCurisNASDAQ:CRISProtara TherapeuticsNASDAQ:TARAEntera BioNASDAQ:ENTXBrainstorm Cell TherapeuticsNASDAQ:BCLIView All CompetitorsInsiders & InstitutionsDavidson Kempner Capital Management LPBought 55,145 shares on 9/12/2023Ownership: 0.000%Renaissance Technologies LLCSold 839,731 shares on 8/11/2023Ownership: 3.735%BlackRock Inc.Sold 128,676 shares on 8/11/2023Ownership: 0.555%Acadian Asset Management LLCSold 648,507 shares on 8/7/2023Ownership: 2.798%Simplex Trading LLCSold 30,600 shares on 8/4/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ACOR Stock - Frequently Asked Questions How have ACOR shares performed in 2023? Acorda Therapeutics' stock was trading at $15.3340 at the start of the year. Since then, ACOR shares have decreased by 2.6% and is now trading at $14.93. View the best growth stocks for 2023 here. Are investors shorting Acorda Therapeutics? Acorda Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 13,300 shares, an increase of 95.6% from the August 31st total of 6,800 shares. Based on an average daily volume of 8,800 shares, the days-to-cover ratio is currently 1.5 days. Currently, 1.1% of the shares of the company are short sold. View Acorda Therapeutics' Short Interest. When is Acorda Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. View our ACOR earnings forecast. How were Acorda Therapeutics' earnings last quarter? Acorda Therapeutics, Inc. (NASDAQ:ACOR) released its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($7.55) earnings per share for the quarter. The biopharmaceutical company earned $29.68 million during the quarter. Acorda Therapeutics had a negative net margin of 17.89% and a negative trailing twelve-month return on equity of 26.63%. When did Acorda Therapeutics' stock split? Acorda Therapeutics's stock reverse split on Monday, June 5th 2023. The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Ron Cohen's approval rating as Acorda Therapeutics' CEO? 39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Acorda Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT). What is Acorda Therapeutics' stock symbol? Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR." Who are Acorda Therapeutics' major shareholders? Acorda Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Davidson Kempner Capital Management LP (0.00%), Renaissance Technologies LLC (3.73%), Acadian Asset Management LLC (2.80%), BlackRock Inc. (0.56%) and Simplex Trading LLC (0.00%). View institutional ownership trends. How do I buy shares of Acorda Therapeutics? Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Acorda Therapeutics' stock price today? One share of ACOR stock can currently be purchased for approximately $14.93. How much money does Acorda Therapeutics make? Acorda Therapeutics (NASDAQ:ACOR) has a market capitalization of $18.51 million and generates $118.57 million in revenue each year. The biopharmaceutical company earns $-65,920,000.00 in net income (profit) each year or ($21.35) on an earnings per share basis. How many employees does Acorda Therapeutics have? The company employs 111 workers across the globe. How can I contact Acorda Therapeutics? Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The official website for the company is www.acorda.com. The biopharmaceutical company can be reached via phone at (914) 347-4300 or via fax at 914-347-4560. This page (NASDAQ:ACOR) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acorda Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.